PTC Therapeutics (NASDAQ:PTCT) Research Coverage Started at Truist Financial

Posted by Stanley Muller on Oct 19th, 2026

Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research report released on Friday morning, MarketBeat.com reports. The brokerage issued a hold rating and a $62.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on PTCT. Cantor Fitzgerald increased their price objective on shares of PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a report on Tuesday, September 22nd. UBS Group reissued a “buy” rating and issued a $90.00 target price (up from $80.00) on shares of PTC Therapeutics in a research report on Thursday. Barclays boosted their target price on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Royal Bank Of Canada dropped their price target on shares of PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, October 7th. Finally, Morgan Stanley increased their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $95.07.

Check Out Our Latest Analysis on PTCT

PTC Therapeutics Stock Performance

PTCT stock opened at $59.24 on Friday. The stock has a market capitalization of $4.94 billion, a P/E ratio of -102.14, a PEG ratio of 1.79 and a beta of 0.49. PTC Therapeutics has a one year low of $58.80 and a one year high of $90.87. The company has a 50 day moving average price of $67.41 and a two-hundred day moving average price of $71.77.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.68. The business had revenue of $360.52 million during the quarter, compared to analyst estimates of $298.63 million. During the same quarter last year, the firm posted ($0.83) earnings per share. The company’s revenue was up 101.5% on a year-over-year basis. Research analysts forecast that PTC Therapeutics will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Glenn Steele, Jr. sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total value of $781,920.00. Following the transaction, the director owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the completion of the transaction, the director owned 1,291,594 shares in the company, valued at $76,991,918.34. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 77,370 shares of company stock valued at $5,322,261. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Allworth Financial LP purchased a new position in PTC Therapeutics in the second quarter valued at about $67,000. EverSource Wealth Advisors LLC lifted its stake in shares of PTC Therapeutics by 16.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 151 shares in the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of PTC Therapeutics during the second quarter worth about $81,000. Quantbot Technologies LP acquired a new position in shares of PTC Therapeutics during the second quarter worth about $112,000. Finally, GAMMA Investing LLC boosted its position in shares of PTC Therapeutics by 58.1% in the second quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 534 shares during the period.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.